Circulation, Vol 87, 70-75, Copyright © 1993 by American Heart Association
T Tsutamoto, T Kanamori, N Morigami, Y Sugimoto, O Yamaoka and M Kinoshita
BACKGROUND. High levels of endogenous atrial natriuretic peptide (ANP) are
thought to compensate the condition of patients with heart failure by
reducing preload and afterload. However, recent reports have indicated that
a high plasma ANP level is a prognostic predictor in patients with heart
failure. Therefore, the role of endogenous ANP has not been clearly
established in patients with heart failure. METHODS AND RESULTS. The plasma
ANP and cGMP levels were determined in the femoral artery and the femoral
vein of 97 patients with chronic congestive heart failure (CHF). The plasma
ANP level decreased significantly, whereas the plasma cGMP levels increased
significantly from the femoral artery to the femoral vein. Among patients
with mild CHF (n = 52), the plasma cGMP level correlated with the ANP
level, and the calculated ANP extraction level also correlated with the
calculated cGMP production in the peripheral circulation (r = 0.70, p <
0.001). In contrast, these correlations were not found in patients with
severe CHF (n = 45). Among these patients, the plasma cGMP levels seemed to
reach a plateau despite high levels of plasma ANP, and the molar ratio of
cGMP production to ANP extraction in the peripheral circulation was
significantly lower than in patients with mild CHF (36.7 +/- 9.5 versus 183
+/- 17, p < 0.001). In patients with acute severe CHF (n = 9) and those
with mild CHF, patients who were administered exogenous ANP, plasma cGMP
levels increased in proportion to those of plasma ANP without saturation.
CONCLUSIONS. These results indicate that downregulation of ANP receptors
coupled to guanylate cyclase may occur in the peripheral vascular beds of
patients with chronic severe CHF.
ARTICLES
Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure
First Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
This article has been cited by other articles:
 |
|
 |
|
  Y. Li, Y. Saito, K. Kuwahara, X. Rong, I. Kishimoto, M. Harada, Y. Adachi, M. Nakanishi, H. Kinoshita, M. Horiuchi, et al. Guanylyl Cyclase-A Inhibits Angiotensin II Type 2 Receptor-Mediated Pro-Hypertrophic Signaling in the Heart Endocrinology, August 1, 2009; 150(8): 3759 - 3765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Klosinska, T. Rudzinski, P. Grzelak, L. Stefanczyk, J. Drozdz, and M. Krzeminska-Pakula Endothelium-dependent and -independent vasodilation is more attenuated in ischaemic than in non-ischaemic heart failure Eur J Heart Fail, August 1, 2009; 11(8): 765 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lourenco, J. P. Araujo, A. Azevedo, A. Ferreira, and P. Bettencourt The cyclic guanosine monophosphate/B-type natriuretic peptide ratio and mortality in advanced heart failure Eur J Heart Fail, February 1, 2009; 11(2): 185 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Dickey, D. R. Flora, P. M. Bryan, X. Xu, Y. Chen, and L. R. Potter Differential Regulation of Membrane Guanylyl Cyclases in Congestive Heart Failure: Natriuretic Peptide Receptor (NPR)-B, Not NPR-A, Is the Predominant Natriuretic Peptide Receptor in the Failing Heart Endocrinology, July 1, 2007; 148(7): 3518 - 3522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Bryan, X. Xu, D. M. Dickey, Y. Chen, and L. R. Potter Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrations Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1636 - F1644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Forfia, M. Lee, R. S. Tunin, M. Mahmud, H. C. Champion, and D. A. Kass Acute Phosphodiesterase 5 Inhibition Mimics Hemodynamic Effects of B-Type Natriuretic Peptide and Potentiates B-Type Natriuretic Peptide Effects in Failing But Not Normal Canine Heart J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1079 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Schwarz, S. Rastogi, V. Kapur, N. Sulemanjee, and J. J. Rodriguez Erectile Dysfunction in Heart Failure Patients J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1111 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tsujita, J. Muraski, I. Shiraishi, T. Kato, J. Kajstura, P. Anversa, and M. A. Sussman Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy PNAS, August 8, 2006; 103(32): 11946 - 11951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Clerico, F. A. Recchia, C. Passino, and M. Emdin Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H17 - H29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fan, P. M. Bryan, L. K. Antos, R. J. Potthast, and L. R. Potter Down-Regulation Does Not Mediate Natriuretic Peptide-Dependent Desensitization of Natriuretic Peptide Receptor (NPR)-A or NPR-B: Guanylyl Cyclase-Linked Natriuretic Peptide Receptors Do Not Internalize Mol. Pharmacol., January 1, 2005; 67(1): 174 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Clerico, M. Emdin, J. P. Goetze, and J. F. Rehfeld Endocrine Paradox in Heart Failure: Resistance to Biological Effects of Cardiac Natriuretic Hormones * Drs. Goetze and Rehfeld respond: Clin. Chem., December 1, 2004; 50(12): 2465 - 2468. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Potthast, S. E. Abbey-Hosch, L. K. Antos, J. S. Marchant, M. Kuhn, and L. R. Potter Calcium-dependent Dephosphorylation Mediates the Hyperosmotic and Lysophosphatidic Acid-dependent Inhibition of Natriuretic Peptide Receptor-B/Guanylyl Cyclase-B J. Biol. Chem., November 19, 2004; 279(47): 48513 - 48519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kuhn, M. Voss, D. Mitko, J. Stypmann, C. Schmid, N. Kawaguchi, F. Grabellus, and H. A. Baba Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure Cardiovasc Res, November 1, 2004; 64(2): 308 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Airhart, Y.-F. Yang, C. T. Roberts Jr., and M. Silberbach Atrial Natriuretic Peptide Induces Natriuretic Peptide Receptor-cGMP-dependent Protein Kinase Interaction J. Biol. Chem., October 3, 2003; 278(40): 38693 - 38698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Garg and K. N. Pandey Angiotensin II-Mediated Negative Regulation of Npr1 Promoter Activity and Gene Transcription Hypertension, March 1, 2003; 41(3): 730 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C Rosenkranz, R. L Woods, G. J Dusting, and R. H Ritchie Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP Cardiovasc Res, February 1, 2003; 57(2): 515 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Johnson, T. Omland, C. Hall, C. Lucas, O. L. Myking, C. Collins, M. Pfeffer, J.-L. Rouleau, and L. W. Stevenson Neurohormonal activation rapidly decreases after intravenous therapy withdiuretics and vasodilators for class IV heart failure J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1623 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R Kalra, S. D Anker, and A. J.S Coats Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin Cardiovasc Res, August 15, 2001; 51(3): 495 - 509. [Full Text] [PDF]
|
|
|
|
|
|
H. Peter Brunner-La Rocca, W. Kiowski, D. Ramsay, and G. Sutsch Therapeutic benefits of increasing natriuretic peptide levels Cardiovasc Res, August 15, 2001; 51(3): 510 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Andreassi, S. Del Ry, C. Palmieri, A. Clerico, A. Biagini, and D. Giannessi Up-regulation of 'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones Eur J Heart Fail, August 1, 2001; 3(4): 407 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.R Kalra, S.D Anker, A.D Struthers, and A.J.S Coats The role of C-type natriuretic peptide in cardiovascular medicine Eur. Heart J., June 2, 2001; 22(12): 997 - 1007. [PDF]
|
|
|
|
 |
|
 K. Maeda, T. Tsutamoto, A. Wada, N. Mabuchi, M. Hayashi, T. Hisanaga, T. Kamijo, and M. Kinoshita Insufficient secretion of atrial natriuretic peptide at acute phase of myocardial infarction J Appl Physiol, August 1, 2000; 89(2): 458 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure J. Am. Coll. Cardiol., March 1, 2000; 35(3): 714 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto, A. Wada, T. Tsutamoto, T. Omura, H. Yokohama, M. Ohnishi, I. Nakae, M. Takahashi, and M. Kinoshita Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H1935 - H1942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsutamoto, A. Wada, T. Hisanaga, K. Maeda, M. Ohnishi, N. Mabuchi, M. Sawaki, M. Hayashi, M. Fujii, and M. Kinoshita Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure J. Am. Coll. Cardiol., February 1, 1999; 33(2): 530 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Lainchbury, A. M. Richards, M. G. Nicholls, E. A. Espiner, and T. G. Yandle Brain Natriuretic Peptide and Neutral Endopeptidase Inhibition in Left Ventricular Impairment J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 723 - 729. [Abstract] [Full Text]
|
|
|
|
 |
|
 S M Maguire, A G Nugent, C McGurk, G D Johnston, and D P Nicholls Abnormal vascular responses in human chronic cardiac failure are both endothelium dependent and endothelium independent Heart, August 1, 1998; 80(2): 141 - 145. [Abstract] [Full Text]
|
|
|
|
|
|
J. G. Lainchbury, A. M. Richards, M. G. Nicholls, P. J. Hunt, H. Ikram, E. A. Espiner, T. G. Yandle, and E. Begg The Effects of Pathophysiological Increments in Brain Natriuretic Peptide in Left Ventricular Systolic Dysfunction Hypertension, September 1, 1997; 30(3): 398 - 404. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Tsutamoto, A. Wada, K. Maeda, T. Hisanaga, Y. Maeda, D. Fukai, M. Ohnishi, Y. Sugimoto, and M. Kinoshita Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart Failure : Prognostic Role of Plasma Brain Natriuretic Peptide Concentration in Patients With Chronic Symptomatic Left Ventricular Dysfunction Circulation, July 15, 1997; 96(2): 509 - 516. [Abstract] [Full Text]
|
|
|
|
|
|
M. Nakamura, H. Yoshida, S. Makita, N. Arakawa, H. Niinuma, and K. Hiramori Potent and Long-Lasting Vasodilatory Effects of Adrenomedullin in Humans: Comparisons Between Normal Subjects and Patients With Chronic Heart Failure Circulation, March 4, 1997; 95(5): 1214 - 1221. [Abstract] [Full Text]
|
|
|
|
|
|
L. S. Marcus, D. Hart, M. Packer, M. Yushak, N. Medina, R. S. Danziger, D. F. Heitjan, and S. D. Katz Hemodynamic and Renal Excretory Effects of Human Brain Natriuretic Peptide Infusion in Patients With Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Crossover Trial Circulation, December 15, 1996; 94(12): 3184 - 3189. [Abstract] [Full Text]
|
|
|
|
|
|
L. Cao, J. Wu, and D. G. Gardner Atrial Natriuretic Peptide Suppresses the Transcription of Its Guanylyl Cyclase-linked Receptor J. Biol. Chem., October 20, 1995; 270(42): 24891 - 24897. [Abstract] [Full Text] [PDF]
|
|